ABSTRACT
Importance Incidence, prevalence, and survival are important measures to inform the management and provision of head and neck cancer care.
Objective To calculate the incidence, prevalence, and survival rates for head and neck cancers and subsites in the UK from 2000 to 2021.
Design, Setting, and Participants This population-based cohort study uses routinely collected primary care data from the UK. Patients aged 18 years or older with at least 1 year of history registered in Clinical Practice Research Datalink (CPRD) GOLD or Aurum were included. Data were analyzed from January 2023 to March 2024.
Main Outcomes and Measures Head and neck cancer incidence rates (IR), period prevalence (PP), and one-, five-, and ten-year survival after diagnosis between 2000 and 2021, stratified by age and calendar years.
Results There were 12,455 HNC patients (male 69.2%) with a median age of 64 years. Crude incidence increased from 9.08 (7.88 to 10.42) per 100 000 person-years in 2000 to 15.59 (14.07 to 17.23) in 2021 in CPRD GOLD with similar rates in Aurum. Age standardization attenuated incidence rises for HNC subsites apart from oropharynx and tongue. Prevalence increased for both databases, from 0.04% in 2000 to 0.12% in 2019. HNC five-year survival increased from 53.8% (95% CI, 51.4% - 56.3%) in 2000-2004 to 58.7% (56.5 - 60.9%) in 2015 to 2019.
Conclusions and Relevance HNC increases over recent decades are likely due to ageing with increases in specific subsites such as oropharyngeal cancers are due to other behavioural risk factors. Small improvements in survival highlights more research is needed to improve earlier diagnosis which will lead to better patient outcomes.
Question What is the disease burden of the head and neck cancers (HNC) in UK from 2000-2021?
Findings For all HNC combined, incidence and prevalence have increased with five-year survival slightly improving over time. Variation in results were observed for different subsites.
Meaning Our findings show increases in HNC are likely due to ageing with increases in certain subsites due to other behavioural risk factors. The small increase in survival highlights more research is needed to improve earlier diagnosis leading to better patient outcomes.
Competing Interest Statement
Professor Daniel Prieto-Alhambra research group has received research grants from the European Medicines Agency, from the Innovative Medicines Initiative, from Amgen, Chiesi, and from UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, Astra Zeneca, and UCB Biopharma. All other authors declare no conflicts of interest.
Funding Statement
This activity under the European Health Data & Evidence Network (EHDEN) and OPTIMA has received funding from the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement No 806968 and No. 101034347 respectively. IMI2 receives support from the European Union's Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA). The sponsors of the study did not have any involvement in the writing of the manuscript or the decision to submit it for publication. Additionally, there was partial support from the Oxford NIHR Biomedical Research Centre. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is based in part on data from the Clinical Practice Research Datalink (CPRD) obtained under licence from the UK Medicines and Healthcare products Regulatory Agency.
The protocol for this research was approved by the Research Data Governance (RDG) Board of the Medicine and Healthcare products Regulatory Agency database research (protocol number 22_001843).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILIABILITY STATEMENT
This study is based in part on data from the Clinical Practice Research Datalink (CPRD) obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the author/s alone. Patient level data used in this study was obtained through an approved application-the CPRD (application number 22_001843) and is only available following an approval process-safeguard the confidentiality of patient data. Details on how to apply for data access can be found at https://cprd.com/data-access.
ABBREVIATIONS
- IR
- incidence rates
- PP
- period prevalence
- HNC
- head and neck cancers
- KM
- Kaplan-Meier
- HPV
- human papillomavirus
